Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP–1RA) in PatientS with Type 2 Diabetes—PROGRESS-DIABETES Study
Authors: BROWN RUTH E. , ABITBOL ALEXANDER , BAJAJ HARPREET S. , KHANDWALA HASNAIN , GOLDENBERG RONALD , ABDEL-SALAM SUZAN , ARONSON RONNIE 
Published: June 2018

This prospective, observational cohort study evaluates patient-reported outcomes (PRO’s) in patients initiating GLP-1 RA therapy in a real-world setting. Patients with type 2 diabetes initiating GLP-1 RA therapy as part of their usual treatment approach were enrolled from Ontario-based LMC Diabetes and Endocrinology clinics. Patients completed questionnaires assessing medication and device satisfaction and medication adherence at baseline and at follow-up (3-6 months). Standard clinical outcomes were collected. To date, 320 subjects have been enrolled: 187 dulaglutide (DULA), 110 liraglutide (LIRA), and 23 switching from LIRA to DULA. At baseline, PRO’s and clinical measures were similar between cohorts (mean age 54.2 ± 10.1 years; mean HbA1c 8.4 ± 1.5%). In this interim analysis of 110 completers to date (mean follow-up 3.3 months), there was a trend for the 77 DULA completers to have greater improvements in PRO scores compared to the 33 LIRA completers (Figure). To-date, DULA subjects had a 1.1 ± 1.0% reduction in HbA1c and 2.2 ± 3.3 kg reduction in weight. The LIRA subjects showed similar trends (1.2 ± 1.0% reduction in HbA1c and 2.4 ± 3.2 kg reduction in weight). Interim analysis of this real-world, specialist-led registry of patients initiating GLP-1 RA therapy showed similar improvements in PRO’s and clinical outcomes.

Disclosure

R.E. Brown: None. A. Abitbol: Research Support; Self; JDRF, JA DeSeve Foundation, Lexicon Pharmaceuticals, Inc., Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; GlaxoSmithKline plc., Merck & Co., Inc.. Consultant; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Research Support; Self; Pfizer Inc., AstraZeneca. Consultant; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; Senseonics, Gilead Sciences, Inc.. Speaker's Bureau; Self; Amgen Inc., Janssen Pharmaceuticals, Inc.. Consultant; Self; Janssen Pharmaceuticals, Inc.. Employee; Self; LMC Diabetes & Endocrinology. Speaker's Bureau; Self; LMC Diabetes & Endocrinology, Valeant Pharmaceuticals International, Inc.. Consultant; Self; Valeant Pharmaceuticals International, Inc. H.S. Bajaj: Speaker's Bureau; Self; Abbott. Advisory Panel; Self; Amgen Inc.. Speaker's Bureau; Self; Amgen Inc.. Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca, Bayer AG. Advisory Panel; Self; Boehringer Ingelheim GmbH. Research Support; Self; Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc., Medtronic. Advisory Panel; Self; Merck & Co., Inc.. Research Support; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc., Mylan. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Valeant Pharmaceuticals International, Inc.. Research Support; Self; Valeant Pharmaceuticals International, Inc.. Speaker's Bureau; Self; Valeant Pharmaceuticals International, Inc. H. Khandwala: Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Novo Nordisk Inc., AstraZeneca. Advisory Panel; Self; Sanofi, Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Other Relationship; Self; Amgen Inc.. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. R. Goldenberg: Advisory Panel; Self; Abbott, Amgen Inc., AstraZeneca. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; Servier. Advisory Panel; Self; Merck & Co., Inc.. S. Abdel-Salam: None. R. Aronson: Other Relationship; Self; Novo Nordisk Inc., Janssen Pharmaceuticals, Inc., Sanofi, AstraZeneca. Research Support; Self; Eli Lilly and Company, Becton, Dickinson and Company, Merck & Co., Inc., Senseonics, Boehringer Ingelheim Pharmaceuticals, Inc..